Invention Grant
![Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors](/docs/US/2023-09-05/US11744832B2/abs.jpg.600x600.jpg)
- Patent Title: Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
-
Application No.: US17689510Application Date: 2022-03-08
-
Publication No.: US11744832B2Publication Date: 2023-09-05
- Inventor: James D. Rodgers , Stacey Shepard
- Applicant: Incyte Corporation , Incyte Holdings Corporation
- Applicant Address: US DE Wilmington
- Assignee: Incyte Corporation,Incyte Holdings Corporation
- Current Assignee: Incyte Corporation,Incyte Holdings Corporation
- Current Assignee Address: US DE Wilmington; US DE Wilmington
- Agency: Fish & Richardson P.C.
- The original application number of the division: US13076220 2011.03.30
- Main IPC: A61K31/519
- IPC: A61K31/519 ; A61K45/06 ; C07B59/00 ; A61K9/00 ; A61K9/20 ; A61P37/00 ; A61P35/04 ; A61P17/04 ; A61P29/00 ; C07D471/04 ; C07D487/04 ; C07D417/04 ; A61K31/573
![Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors](/abs-image/US/2023/09/05/US11744832B2/abs.jpg.150x150.jpg)
Abstract:
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Public/Granted literature
- US20220395506A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS Public/Granted day:2022-12-15
Information query
IPC分类:
